Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy

[1] Sakane T(1999)Behçet’s disease N Engl J Med. 341 1284-1291

[2] Takeno M(1997)Uveitis in Behçet’s disease Int Rev Immunol. 14 67-79

[3] Suzuki N(1997)Ocular immunopathology of Behçet’s disease Surv Ophthalmol. 42 157-162

[4] Inaba G(2005)Risk and prognostic factors of poor visual outcome in Behçet’s disease Graefe’s Arch Clin Exp Ophthalmol. 243 1147-1152

[5] Nussenblatt RB(1997)Immunotherapy for Behçet’s disease Int Rev Immunol. 14 49-66

[6] George RK(2004)Uveitis in Behçet’s disease: an analysis of 880 patients Am J Ophthalmol. 138 373-380

[7] Chan CC(2004)Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis J Rheumatol. 31 1362-1368

[8] Whitcup SM(2005)Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial Arthritis Rheum. 52 2478-2484

[9] Nussenblatt RB(2005)Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease Int Ophthalmol. 26 83-92

[10] Takeuchi M(2007)Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease Jpn J Ophthalmol. 51 53-57

[1] Sakane T(1999)Behçet’s disease N Engl J Med. 341 1284-1291

[2] Takeno M(1997)Uveitis in Behçet’s disease Int Rev Immunol. 14 67-79

[3] Suzuki N(1997)Ocular immunopathology of Behçet’s disease Surv Ophthalmol. 42 157-162

[4] Inaba G(2005)Risk and prognostic factors of poor visual outcome in Behçet’s disease Graefe’s Arch Clin Exp Ophthalmol. 243 1147-1152

[5] Nussenblatt RB(1997)Immunotherapy for Behçet’s disease Int Rev Immunol. 14 49-66

[6] George RK(2004)Uveitis in Behçet’s disease: an analysis of 880 patients Am J Ophthalmol. 138 373-380

[7] Chan CC(2004)Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis J Rheumatol. 31 1362-1368

[8] Whitcup SM(2005)Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial Arthritis Rheum. 52 2478-2484

[9] Nussenblatt RB(2005)Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease Int Ophthalmol. 26 83-92

[10] Takeuchi M(2007)Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease Jpn J Ophthalmol. 51 53-57